Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer. (23rd July 2021)
- Record Type:
- Journal Article
- Title:
- Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer. (23rd July 2021)
- Main Title:
- Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer
- Authors:
- Tsuzuki, Shunsuke
Kawano, Shota
Fukuokaya, Wataru
Mori, Keiichiro
Nishikawa, Hideomi
Tashiro, Kojiro
Watanabe, Daisuke
Uchimoto, Taizo
Nishimura, Kazuki
Yano, Yusuke
Murakami, Masaya
Koike, Yusuke
Hata, Kenichi
Koide, Haruhisa
Miki, Jun
Abe, Hirokazu
Yamada, Hiroki
Naruoka, Takehito
Sugaya, Shingo
Kimura, Takahiro
Tomita, Masayuki
Nakajo, Hiroshi
Egawa, Shin - Abstract:
- Abstract: Background: Randomized trials showed the survival benefits of the combined use of androgen receptor axis-targeted agents with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer (mHSPC), regardless of the risk. However, treating patients with low-risk mHSPC with such intensive treatment is still debatable. Methods: This retrospective study included 155 low-risk patients among 467 mHSPC patients treated in our affiliated institutions. The association between predictive factors and treatment outcomes was estimated using the Kaplan–Meier method and log-rank test. Predictive factors for castration resistant prostate cancer (CRPC)-free survival were investigated using Cox regression analyses. Results: During the median follow-up of 39 months, 38.7% of patients developed CRPC and 14.2% died. In the multivariate analyses, a presence of Gleason pattern 5 (hazard ratio [HR] 2.04), high alkaline phosphatase (HR 1.007) and high lactate dehydrogenase (HR 1.009) were significant predictive factors for shorter CRPC-free survival. Finally, 155 patients were stratified into favorable- and unfavorable-risk groups based on the numbers of the predictive factors. The overall survival (OS) in the unfavorable-risk group (total scores: 2–3) was significantly worse than that of the favorable-risk group (total score: 0–1) ( P = 0.02). This prognostic model was assessed with 50 low-risk mHSPC patients from the external validation dataset and found both the time toAbstract: Background: Randomized trials showed the survival benefits of the combined use of androgen receptor axis-targeted agents with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer (mHSPC), regardless of the risk. However, treating patients with low-risk mHSPC with such intensive treatment is still debatable. Methods: This retrospective study included 155 low-risk patients among 467 mHSPC patients treated in our affiliated institutions. The association between predictive factors and treatment outcomes was estimated using the Kaplan–Meier method and log-rank test. Predictive factors for castration resistant prostate cancer (CRPC)-free survival were investigated using Cox regression analyses. Results: During the median follow-up of 39 months, 38.7% of patients developed CRPC and 14.2% died. In the multivariate analyses, a presence of Gleason pattern 5 (hazard ratio [HR] 2.04), high alkaline phosphatase (HR 1.007) and high lactate dehydrogenase (HR 1.009) were significant predictive factors for shorter CRPC-free survival. Finally, 155 patients were stratified into favorable- and unfavorable-risk groups based on the numbers of the predictive factors. The overall survival (OS) in the unfavorable-risk group (total scores: 2–3) was significantly worse than that of the favorable-risk group (total score: 0–1) ( P = 0.02). This prognostic model was assessed with 50 low-risk mHSPC patients from the external validation dataset and found both the time to CRPC, and the OS in the unfavorable-risk group was significantly worse than that of the favorable-risk group ( P < 0.01). Conclusions: The combination of Gleason pattern 5, high alkaline phosphatase and lactate dehydrogenase can predict those with worse OS in low-risk mHSPC patients. Abstract : Assessment of Gleason score, ALP, and LDH can predict worse survivors in low-risk mHSPC patients. … (more)
- Is Part Of:
- Japanese journal of clinical oncology. Volume 51:Number 11(2021)
- Journal:
- Japanese journal of clinical oncology
- Issue:
- Volume 51:Number 11(2021)
- Issue Display:
- Volume 51, Issue 11 (2021)
- Year:
- 2021
- Volume:
- 51
- Issue:
- 11
- Issue Sort Value:
- 2021-0051-0011-0000
- Page Start:
- 1665
- Page End:
- 1671
- Publication Date:
- 2021-07-23
- Subjects:
- alkaline phosphatase -- Gleason score -- lactate dehydrogenase -- low-risk metastatic hormone-sensitive prostate cancer -- survival
Oncology -- Periodicals
Cancer -- Periodicals
616.994005 - Journal URLs:
- http://jjco.oupjournals.org/ ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/jjco/hyab115 ↗
- Languages:
- English
- ISSNs:
- 0368-2811
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4651.378000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19698.xml